34 results
DEFA14A
VIR
Vir Biotechnology Inc
14 May 24
Additional proxy soliciting materials
4:05pm
combined GAAP R&D and SG&A expenses; and the Company’s plans for its CHD, CHB, human immunodeficiency virus (HIV), RSV/MPV, Influenza, pre-cancerous … research and development efforts; the timing and amount of actual expenses, including, without limitation, the Company’s anticipated combined GAAP R&D
8-K
EX-99.1
VIR
Vir Biotechnology Inc
2 May 24
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:09pm
plans to host a virtual R&D day in late November.
Effective May 3, 2024, Sung Lee, Executive Vice President and Chief Financial Officer will be stepping … of sotrovimab.
Research and Development Expenses (R&D): R&D expenses for the first quarter of 2024 were $100.1 million, which included $13.6 million of non
8-K
EX-99.1
22wmqp9h4dwgr5ti6e
22 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:12pm
8-K
EX-99.1
d9c2yyniietyeaoshg2
2 Nov 23
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:09pm
8-K
EX-99.1
2biht4k dl6ts
3 Aug 23
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:14pm
8-K
EX-99.1
cqm7hs7
4 May 23
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:16pm
8-K
EX-99.1
46fp 13nc5l
9 Aug 22
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
wtuug
5 May 22
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
12:00am
8-K
EX-99.2
tcmbknvgp14kxx016
24 Feb 22
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
4:27pm